Modified CV Regimen in Optic Pathway Glioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Optic GliomaPediatric Brain Tumor, Optic Nerve Glioma
Interventions
DRUG

Carboplatin

Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).

DRUG

Vincristine

Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.

DRUG

Recombinant human endostatin

Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Capital Medical University Sanbo Brain Hospital, Beijing

All Listed Sponsors
lead

Beijing Sanbo Brain Hospital

OTHER